Neoadjuvant docetaxel augments the efficacy of preoperative docetaxel/cyclophosphamide in operable breast cancer: First results of NSABP B-27

Clinical Breast Cancer

Volumn 2, Issue 4, 2002, Pages 266-268

  D'Orazio, Amy I ^a   O'Shaughnessy, Joyce ^a   Seidman, Andrew D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; NEEDLE BIOPSY; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036191632     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70423-2     Document Type: Article

References (4)

1. Management of locally advanced carcinoma of the breast
2. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma
3. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
4. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27